Split Tolerance

Split tolerance—also termed dissociated tolerance or partial immunological tolerance—is an immunological state in which a host organism maintains durable antigen-specific unresponsiveness within one compartment of the adaptive immune system or toward one tissue lineage of an allogeneic donor, while simultaneously mounting an active immune response via a distinct effector arm or against a different tissue from the same donor or pathogen. First described by Gustav Nossal, Leslie Brent, Peter Medawar, and J. B. Solomon in the late 1950s and formalized by Edward A. Boyse, H. Festenstein, and Leslie Brent during early neonatal allogeneic chimerism studies, split tolerance demonstrates that immunological tolerance is neither monolithic nor uniform across lymphocyte lineages, effector classes, or anatomical tissue beds. Instead, differential activation thresholds, tissue-restricted polymorphic antigens, and local regulatory microenvironments govern whether T lymphocytes and B lymphocytes undergo deletion, anergy, or effector differentiation.

Neonatal Chimerism and the Dissociation of Graft Survival from Humoral Immunity

In classic experiments following the 1953 discovery of neonatal acquired tolerance by Rupert Billingham, Leslie Brent, and Peter Medawar, investigators observed that newborn mice injected with semi-allogeneic or fully allogeneic adult splenocytes frequently developed partial rather than complete tolerance. Specifically, Brent and Courtenay (1962) and Warner (1964) documented two canonical dimensions along which tolerance splits:

1. Lineage- or Tissue-Restricted Split Tolerance (Hematopoietic vs. Parenchymal Dissociation): Mice rendered neonatally chimeric by infusion of allogeneic bone marrow or spleen cells retained stable mixed donor–host hematopoietic chimerism in their blood, bone marrow, and lymphoid organs and remained tolerant to donor major histocompatibility complex (MHC) antigens, yet rejected skin allografts or cardiac grafts transplanted from the exact same donor strain.
2. Effector-Arm Split Tolerance (Cellular vs. Humoral Dissociation): Animals or human recipients exposed to low-dose soluble protein antigens, oral tolerogens, or non-cytopathic persistent viruses displayed complete abrogation of delayed-type hypersensitivity (DTH, T_H1 cellular immunity) or cytotoxic CD8⁺ T-cell lysis while continuing to synthesize high-titer antigen-specific IgG1/IgE antibodies—or, conversely, retained intact T-cell cytotoxicity while failing to mount neutralizing humoral responses.

Differential Antigen Thresholds Between T and B Lymphocytes (The Weigle Principle)

In 1971, William O. Weigle and Jacques M. Chiller quantified the kinetics of tolerance induction and spontaneous recovery in thymic T cells versus bone-marrow B cells using deaggregated human gamma globulin (dHGG) in adult mice. Their experiments established that T and B lymphocytes obey fundamentally different dose and kinetic thresholds:

• T-Cell Tolerance Kinetics: CD4⁺ helper T cells are rendered tolerant within 24 hours of exposure to low doses of soluble tolerogen (10–100 μg of dHGG) and remain unresponsive for 100 to 150 days.
• B-Cell Tolerance Kinetics: B lymphocytes require 100- to 1,000-fold higher antigen concentrations (1–10 mg of dHGG) and 3 to 15 days of continuous exposure to undergo clonal deletion or anergy, and the B-cell compartment recovers responsiveness within 40 to 50 days via rapid de novo lymphopoiesis in the bone marrow.

Consequently, at low concentrations of self-antigens or during the waning phase of exogenous tolerogen administration, a long window of T–B split tolerance exists in which self-reactive B cells are fully functional while helper T cells remain tolerant. If a pathogen bearing a structurally homologous B-cell epitope linked to a foreign carrier protein infects the host during this window (molecular mimicry), pathogen-specific CD4⁺ T cells bypass the tolerized self-T-cell pool and provide cognate help to the nontolerant B cells, precipitating autoantibody production.

Tissue-Restricted Polymorphic Antigens and Mixed Hematopoietic Chimerism

In transplantation immunology, establishing mixed hematopoietic chimerism via non-myeloablative bone marrow transplantation enables donor-derived dendritic cells to seed the recipient thymus and delete donor-reactive thymocytes through negative selection (central tolerance). However, mixed chimeras frequently exhibit split tolerance toward donor skin allografts while permanently accepting donor hematopoietic cells and donor kidney or heart grafts. Three complementary mechanisms account for this dissociation:

1. Skin-Specific Minor Histocompatibility Antigens: Epidermal keratinocytes and hair follicle cells express tissue-restricted polymorphic minor histocompatibility peptides (such as Epa-1 and Sk antigens) that are not transcribed at sufficient levels by bone-marrow-derived thymic dendritic cells or AIRE⁺ medullary thymic epithelial cells. CD8⁺ T cells specific for these epidermal peptides escape central deletion and attack skin grafts upon grafting.
2. Danger Signals and Resident Langerhans Cell Immunogenicity: Surgical placement of a full-thickness skin graft induces ischemic necrosis, toll-like receptor (TLR) signaling, and emigration of donor epidermal Langerhans cells expressing high levels of CD80, CD86, and IL-12, overriding local Foxp3⁺ T_reg suppression and breaking infectious tolerance and linked suppression.
3. Endothelial Cross-Dressing and Indirect Allorecognition: Even when direct CD8⁺ alloreactivity against donor hematopoietic cells is deleted, recipient dendritic cells can acquire intact donor MHC complexes via cross-dressing or process shed polymorphic donor proteins via indirect presentation to stimulate residual alloreactive CD4⁺ T cells and donor-specific alloantibodies.

Immune Deviation and Anterior Chamber-Associated Immune Deviation (ACAID)

Split tolerance also arises physiologically in immunologically privileged anatomical sites such as the anterior chamber of the eye, the pregnant uterus (maternal-fetal microchimerism), and the gastrointestinal mucosa. As characterized by J. Wayne Streilein, introducing foreign antigen into the ocular anterior chamber triggers anterior chamber-associated immune deviation (ACAID): intraocular TGF-β2-conditioned F4/80⁺ antigen-presenting cells migrate via the bloodstream to the splenic marginal zone, where they interact with invariant natural killer T (iNKT) cells, marginal zone B cells, and CD4⁺/CD8⁺ regulatory T cells. The resulting systemic split tolerance selectively suppresses tissue-destructive delayed-type hypersensitivity (DTH) and complement-fixing antibodies (such as murine IgG2a/IgG2b) that would blind the eye through corneal inflammation, while preserving non-complement-fixing neutralizing IgG1 antibodies and cytotoxic T-cell precursors.

Viral Persistence and Dissociated Antiviral Immunity

Non-cytopathic persistent viruses—including lymphocytic choriomeningitis virus (LCMV) in mice and hepatitis B virus (HBV) or hepatitis C virus (HCV) in humans—exploit split tolerance to maintain chronic infection without killing the host. As demonstrated by Rolf Zinkernagel and Hans Hengartner, persistent high-titer viral replication systematically deletes or exhausts high-avidity virus-specific CD8⁺ cytotoxic T lymphocytes (CTLs) via chronic TCR stimulation and PD-1/LAG-3 upregulation (preventing fatal T-cell-mediated choriomeningitis or fulminant hepatic necrosis), while virus-specific CD4⁺ T_FH cells and B cells continue to generate antiviral antibodies or immune complexes. Conversely, in neonatal vertical transmission of HBV, circulating secreted hepatitis B e antigen (HBeAg) crosses the placenta to tolerize HBeAg/HBcAg-specific T_H1 cells in utero, creating a split tolerance state that permits decades of high-titer viral replication with minimal liver inflammation during the "immunotolerant" phase of chronic HBV infection.

How does split tolerance differ from complete immunological tolerance and immune exhaustion?

Complete immunological tolerance (such as thymic clonal deletion of self-reactive lymphocytes to a ubiquitously expressed protein) silences both cellular (CD4⁺ T_H1, CD8⁺ CTL) and humoral (B-cell/antibody) responses across all tissues. Split tolerance, by contrast, is compartmentalized: one effector arm (e.g., skin graft rejection or IgG1 antibody production) remains active while another arm (e.g., bone marrow graft acceptance or delayed-type hypersensitivity) is completely unresponsive to the same donor or antigen. Unlike global T-cell exhaustion—where all effector functions of a single clone progressively decay under chronic antigen load—split tolerance reflects divergent fate decisions between distinct lymphocyte subsets or tissue antigens.

Why can a mixed bone-marrow chimera reject a donor skin graft while retaining donor blood cells?

Donor hematopoietic stem cells engrafted in the recipient bone marrow continuously generate donor leukocytes and thymic dendritic cells, which delete T cells reactive to shared donor MHC and ubiquitous minor histocompatibility antigens. However, skin grafts express tissue-restricted polymorphic peptides unique to epidermal keratinocytes and trigger acute surgical inflammation via resident Langerhans cells. Recipient T cells specific for these skin-restricted peptides are not deleted by hematopoietic cells in the thymus and selectively destroy the skin graft while sparing donor blood cells that lack those epidermal antigens.

Why does split tolerance between T cells and B cells predispose hosts to autoimmunity?

Because CD4⁺ T cells become tolerant at 100- to 1,000-fold lower self-antigen concentrations than B cells (the Weigle principle), many self-proteins present at low physiological concentrations in serum or extracellular fluid tolerize only the CD4⁺ T-cell compartment while leaving self-reactive B cells functionally intact. If an infection introduces a microbial antigen that shares a B-cell epitope with the self-protein alongside foreign T-cell epitopes, foreign-reactive T_H cells can supply CD40L and IL-21 help to the nontolerant self-reactive B cells, breaking humoral tolerance.

1. Chiller, J. M., Habicht, G. S., & Weigle, W. O. (1971). "Kinetic differences in unresponsiveness of thymus and bone marrow cells." Science, 171(3973), 813–815. https://doi.org/10.1126/science.171.3973.813
2. Sprent, J., Hurd, M., Schaefer, M., & Heath, W. (1995). "Split tolerance in spleen chimeras." The Journal of Immunology, 154(3), 1198–1206. https://doi.org/10.4049/jimmunol.154.3.1198
3. Chan, W. F., Perez-Cunningham, J., & Anderson, C. C. (2008). "Understanding split tolerance after hematopoietic stem cell transplantation." Transplantation, 85(12), 1699–1705. https://doi.org/10.1097/TP.0b013e3181775425
4. Streilein, J. W. (2003). "Ocular immune privilege: therapeutic opportunities from an experiment of nature." Nature Reviews Immunology, 3(11), 879–889. https://doi.org/10.1038/nri1224